It’s has been an intensive, challenging and surreal start to the year. With the Corona virus pandemic, our focus has turned to protecting and taking care of ourselves, our loved ones, our colleagues and our communities. We all need to take individual responsibility to follow public health guidelines and to do what we can to help slow down and reduce the spread of the virus.
The BioVentureHub (BVH) team is working remotely to ensure our business and operations are continued with minimal disruption. Our capabilities (and love for) online digital tools and virtual meetings have gone from almost zero to almost hero overnight!
We’re making sure the BioVentureHub companies receive the same information as AstraZeneca (AZ) staff at the AZ Gothenburg site, and we are in regular contact with the companies to provide support and guidance in these difficult times.
Before the onset of the virus, the BioVentureHub was getting off to a flying start to the year:
We announced a collaboration between the BioVentureHub and IBM Sweden to strengthen digital health expertise. Through the collaboration, small and medium-sized enterprises (SMEs) connected to IBM Sweden or AstraZeneca’s BioVentureHub will be offered access to the other partner’s open innovation platform. OnDosis is the first BVH company to have been selected for the IBM program.
We have been compiling the results of a survey of the BVH companies. We are delighted that the BVH has an overall satisfaction rating of 9.16 out of 10 from the companies, and we received some really useful ideas and feedback about how we can continue to generate value and collaboration opportunities for the companies, for AstraZeneca and for the life science industry as a whole.
Three new companies have joined the BVH: Amferia, Emotra and Intelligent Implants and we are currently finalizing agreements with a number of exciting companies that will enter the BVH in Q2, exposing AstraZeneca to more new science and technologies; and adding to the 4D (drugs, devices, diagnostics, digital solutions) life science environment we are catalyzing.
There are currently 27 companies and 1 academic group co-locating with us at the AstraZeneca Gothenburg site.
We’re super happy that our neighbours, friends and collaboration partners at GoCo Health Innovation broke ground in January on their first new building and welcomed Japanese cancer diagnostics company Fujirebio as their first new tenant.
We’re proud to have hosted a visit from the US ambassador, Ken Howery, a workshop on risk capital and financing for growth companies by IKEM (an organization representing Swedish chemical and innovation companies) and a seminar on sustainability for the BVH companies during the first three months of the year.
Here are seven cool success stories from BVH companies during the first quarter of 2020:
Amferia raised SEK 6.2 million in investment from Almi Invest, Chalmers Ventures and Business Angels for the company’s innovative wound care patches that kill antibiotic resistant bacteria.
Athera Biotechnologies is included on a list of SwedenBIO companies working with projects to develop new treatments for Covid-19 patients.
Cellink has been involved in a project to develop the first 3D printed bionic pancreas.
Datametrix announced a collaboration with Clinerion to deliver Real World Evidence (RWE) insights from Real World Data (RWD) from Clinerion’s global hospital network through the use of Datametrix’s analytical capabilities.
InSingulo Solutions has been granted SEK 2 million for “Next generation biosensor for drug development” from the Vinnova program: "Innovation projects in SMEss – autumn 2019."
OnDosis is one of the finalists in the RESI Europe Innovation Challenge.
Again, thank you so much for your continued support and encouragement. It is sincerely appreciated.
For more information about the BioVentureHub, please see:
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes.